7月30日,中国国家药监局(NMPA)官网最新公示,李氏大药厂旗下子公司兆科肿瘤申报的抗PD-L1单克隆抗体索卡佐利单抗新适应症上市申请已获得批准。根据李氏大药厂公开资料可知,该药本次获批的适应症为联合化疗一线治疗广泛期小细胞肺癌。截图来源:NMPA官网索卡佐利单抗是一款全人源PD-L1人免疫球蛋白G1(IgG1)单抗,其保留了完整Fc端,抗体依赖的细胞介导的细胞毒性(ADCC)作用作为次要作用...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.